{"nctId":"NCT00558025","briefTitle":"Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease","startDateStruct":{"date":"2007-10"},"conditions":["Parkinson Disease"],"count":156,"armGroups":[{"label":"Pramipexole Extended Release (ER)","type":"EXPERIMENTAL","interventionNames":["Drug: Pramipexole Extended Release"]},{"label":"Pramipexole Immediate Release (IR)","type":"EXPERIMENTAL","interventionNames":["Drug: Pramipexole Immediate Release"]}],"interventions":[{"name":"Pramipexole Extended Release","otherNames":[]},{"name":"Pramipexole Immediate Release","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female patient with idiopathic Parkinson's disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.\n2. Parkinson's disease diagnosed within 5 years.\n3. Patients 30 years of age or older at the time of diagnosis.\n4. Modified Hoehn and Yahr stage of 1 to 3.\n5. Patients receiving pramipexole IR for at least three months prior to baseline visit (randomization visit, V2).\n6. Pramipexole dose should be optimized (according investigator¿s judgement), greater or equal to 1.5 mg/day, stable and equally divided 3 times per day, for a least 4 weeks prior to baseline visit (V2).\n7. Patients willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.\n8. Signed informed consent obtained before any study procedures are carried out in accordance with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines and local legislation).\n\nExclusion Criteria:\n\n1. Motor complications under levodopa therapy at V1.\n2. Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.\n3. Dementia, as defined by a Mini-Mental State Exam score \\< 24 at V1\n4. Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria\n5. History of psychosis, except history of drug induced hallucinations\n6. Clinically significant electrocardiogram (ECG) abnormalities at V1.\n7. Clinically significant hypotension either at screening visit or at baseline visit.\n8. Malignant melanoma or history of previously treated malignant melanoma.\n9. Any other clinically significant disease\n10. Pregnancy or breast-feeding.\n11. Sexually active female of childbearing potential\n12. Serum levels of Aspartate Aminotransferase (Serum Glutamic Oxaloacetic Transaminase) (AST (SGOT)), Alanine Aminotransferase (Serum Glutamate Pyruvate Transaminase) (ALT (SGPT)), alkaline phosphatases or bilirubin \\> 2 Upper Limit of Normal (ULN) (on screening lab test).\n13. Patients with a creatinine clearance \\< 50 mL/min\n14. Any dopamine agonist (except pramipexole IR) within three months prior to baseline visit.\n15. History of discontinuation of treatment with pramipexole IR\n16. Previous treatment with pramipexole ER.\n17. Any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit (i.e. typical neuroleptics, atypical antipsychotics, reserpine, methyldopa, centrally-active antiemetics, etc).\n18. Any of the following drugs within 4 weeks prior to the baseline visit: methylphenidate, cinnarizine, amphetamines.\n19. Flunarizine within 3 months prior to baseline visit.\n20. Known hypersensitivity to Pramipexole or its excipients.\n21. Drug abuse (including alcohol), according to Investigator¿s judgement, within 2 years prior to screening.\n22. Participation in other investigational drug studies or use of other investigational drugs within 4 weeks or five times the half-life of the investigational drug (whichever is longer) prior to baseline visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Who Successfully Switched From Pramipexole Immediate Release (IR) to Pramipexole ER After a Possible Dose Adaptation, Full Analysis Set (FAS), Last Observation Carried Forward (LOCF)","description":"A successful switch was defined by no change of the Unified Parkinson's Disease Rating Scale (UPDRS) II+III by more than 15% from baseline to week 9, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"94.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Successfully Switched From Pramipexole IR to Pramipexole ER With no Dose Adaptation, FAS (LOCF)","description":"A successful switch was defined by no change of the UPDRS II+III by more than 15% from baseline to week 4, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in UPDRS Part II+III Total Score at Week 9, FAS (LOCF)","description":"Unified Parkinson's Disease Rating Scale part II+III total score on FAS, Week 9 - baseline, UPDRS II+III score ranging from 0 (no impairment) to 160 (worst impairment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"0.5"},{"groupId":"OG001","value":"-0.5","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in UPDRS Part II Total Score at Week 9, FAS (LOCF)","description":"Unified Parkinson's Disease Rating Scale part II total score on FAS, Week 9 - baseline, UPDRS II score ranging from 0 (no impairment) to 52 (worst impairment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.2"},{"groupId":"OG001","value":"-0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in UPDRS Part III Total Score at Week 9, FAS (LOCF)","description":"Unified Parkinson's Disease Rating Scale part III total score on FAS, week 9 - baseline, UPDRS II+III score ranging from 0 (no impairment) to 108 (worst impairment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.4"},{"groupId":"OG001","value":"-0.3","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression - Improvement (CGI-I), FAS (LOCF)","description":"Clinical Global Impression - Improvement on FAS, CGI-I was rated from 1: very much improved, to 7: very much worse, CGI-I responder are defined as being rated as 'unchanged', 'minimally improved', 'much improved', or 'very much improved', CGI-I non-responder are defined as being rated 'minimally worse', 'much worse' or 'very much worse'","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression - Improvement (PGI-I), FAS (LOCF)","description":"Patient Global Impression - Improvement on FAS, PGI-I was rated from 1: very much better, to 7: very much worse, PGI-I responder are defined as being rated as 'unchanged', 'minimally better', 'much better', or 'very much better', PGI-I non-responder are defined as being rated as 'minimally worse', 'much worse', or 'very much worse'","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Pramipexole Dose Adaptation, FAS (LOCF)","description":"Patients with increase in daily Pramipexole dose on FAS","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Final Pramipexole Dose (mg) After 9 Weeks, Treated Set","description":"The mean final daily Pramipexole dose is displayed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.75","spread":"0.95"},{"groupId":"OG001","value":"2.83","spread":"0.86"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":104},"commonTop":[]}}}